First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
HER2-positive Gastric Cancer
DRUG: Disitamab vedotin|DRUG: Tislelizumab|DRUG: S1
objective response rate (ORR), The proportion of subjects with complete response (CR) and partial response (PR) in total subjects, 6 months after the last subject participating in
progression-free survival (PFS), Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first, 12 months after the last subject participating in|overall survival (OS), OS is defined as the time from the starting date of study drug to the date of death due to any cause., 12 months after the last subject participating in|disease control rate (DCR), The proportion of subjects with complete response (CR) and partial response (PR) and stable disease(SD)in total subjects, 12 months after the last subject participating in|duration of response (DOR), DOR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first., 12 months after the last subject participating in
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.